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Background: Mild to moderate cognitive impairment is common amongst long-term survivors of cardiac arrest. In
the Target Temperature Management trial (TTM-trial) comatose survivors were randomized to 33°C or 36°C
temperature control for 24 hours after cardiac arrest and the effects on survival and neurological outcome assessed.
This protocol describes a sub-study of the TTM-trial investigating cognitive dysfunction and its consequences for
patients’ and relatives’ daily life.
Methods/Design: Sub-study sites in five European countries included surviving TTM patients 180 days after cardiac
arrest. In addition to the instruments for neurological function used in the main trial, sub-study patients were
specifically tested for difficulties with memory (Rivermead Behavioural Memory Test), attention (Symbol Digit
Modalities Test) and executive function (Frontal Assessment Battery). Cognitive impairments will be related to the
patients’ degree of participation in society (Mayo-Portland Adaptability Inventory-4), health related quality of life
(Short Form Questionnaire–36v2©), and the caregivers’ situation (Zarit Burden Interview©). The two intervention
groups (33°C and 36°C) will be compared with a group of myocardial infarction controls.
Discussion: This large international sub-study of a randomized controlled trial will focus on mild to moderate
cognitive impairment and its consequences for cardiac arrest survivors and their caregivers. By using an additional
battery of tests we may be able to detect more subtle differences in cognitive function between the two
intervention groups than identified in the main study. The results of the study could be used to develop a relevant
screening model for cognitive dysfunction after cardiac arrest.
Trial registration: ClinicalTrials.gov: NCT01946932.
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Out of hospital cardiac arrest (OHCA) is common and a
major cause of death. Even when resuscitation is successful,
there is still an attributable risk for subsequent death [1].
The brain is particularly susceptible to circulatory arrest
and hypoxic-ischemic brain injury accounts for approxi-
mately 70% of the in-hospital mortality of cardiac arrest
(CA) patients admitted to intensive care [2]. Survival with
severe neurological disability is uncommon, presumably
due to withdrawal of life-supporting treatments (WLST) in
patients in whom it is assumed that prognosis is poor [2].
However, studies investigating cognitive function have
demonstrated that a large proportion of the survivors
are affected by mild to moderate cognitive dysfunction at
3–6 months after cardiac arrest. There is considerable vari-
ability in the prevalence of impairment observed in earlier
studies, however many of these were limited by small study
samples size and the use of tests with insufficient sensitivity
to detect mild to moderate cognitive impairment [3]. Some
high quality studies show that about half of the CA survi-
vors are left with long-term cognitive impairment, typically
involving memory, executive functions and attention [3].
Cognitive dysfunction is known to affect the daily life
of patients and their families [3-7]. Most CA survivors
perform their basic activities of daily living (ADL) with-
out any significant problems [4]. However, participation
in society exemplified by the ability to maintain roles in
social, family, home, financial, work or education do-
mains [8] may be considerably affected with as many as
74% of CA survivors having reduced levels of involve-
ment [4]. Participation in the society is related to quality
of life and is highly valued by patients, their relatives
and society [9,10].
Induced hypothermia was recommended as a neuro-
protective treatment after OHCA [11] following clinical
trials showing a beneficial effect on neurological out-
come [12,13] and survival [13]. However, a systematic
review and trial sequential analyses concluded that the
evidence was insufficient and that a larger trial to con-
firm an effect on survival was needed [14]. Whether or
not induced hypothermia has an effect on cognitive
function has been inadequately investigated. The two
key trials [12,13] defined good outcome as Cerebral
Performance Categories (CPC) 1–2 [13] or as discharge
to home or a rehabilitation centre [12]. Although these
outcome measures may detect differences in mortality and
severe brain injury, they are clearly insensitive to differenti-
ate between commoner mild to moderate neurological im-
pairment. The CPC score has been found to overestimate
favourable outcome, especially when based on hospital dis-
charge records [15-18]. The outcome measure “discharge
to a rehabilitation centre” has obvious shortcomings since
it may include a range of neurological disability, depending
on the evaluation of rehabilitation potential and resources.Only one randomized study has made a direct com-
parison between CA patients treated with or without
hypothermia using sensitive cognitive tests [16]. In this
sub-study of the HACA trial [13], 67% of patients in the
hypothermia group had normal or mildly impaired cog-
nition compared to 44% in the control group. This was
not statistically significant, possibly due to the small
sample size of only 27 hypothermia treated and 18 con-
trol patients.
The Target Temperature Management trial (TTM) is a
large randomized, parallel group assessor blinded multi-
centre study that compares the effects of two strict
temperature regimes, 33°C and 36°C for 24 hours after
CA. The primary outcome measure is survival, and the
secondary outcomes are neurological function and health
related quality of life (HRQoL) [19]. This pragmatic trial
offers a unique possibility to study cognitive dysfunction
in a large international sample of OHCA. The TTM main
follow-up component is limited to simple tests and ques-
tionnaires. This manuscript presents the rationale and
methods of a sub-study of the TTM trial, designed to
evaluate cognitive impairment and their impact on partici-
pation in society, as well as the next-of-kin’s HRQoL and
perception of burden.
Aims and hypotheses
Our primary aim is to test the hypothesis that cognitive
impairment will be less pronounced amongst patients
treated with 33°C compared to those treated with 36°C
due to a postulated neuroprotective effect of hypothermia,
and that both groups of CA patients will have more
cognitive impairment than the matched group of controls
without CA.
Other hypotheses of this sub-study are that patients
with cognitive impairment will have a lower level of par-
ticipation in the society and a lower HRQoL than CA
patients without cognitive impairment and controls.
Finally, we hypothesize that cognitive impairment will
decrease the caregivers’/relatives’ HRQoL and increase
their perception of burden.
Methods/Design
Study design
This is a prospective, randomized and pre-registered sub-
study of the TTM-trial approved by the TTM-steering
group. The TTM-trial started recruitment in November
2010 and reached the inclusion target at 950 patients in
January 2013 [19]. At 180 days (± 2 weeks) after cardiac ar-
rest, all TTM survivors attended a face-to-face follow-up
to evaluate their neurological function and HRQoL [19].
During this follow-up meeting, patients and their represen-
tatives included in the sub-study performed additional
assessments relating to cognitive function, participation in
society, caregiver HRQoL and estimated burden. The
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ment temperature allocation, but control patients were
identified as such.
Setting
In this sub-study, 20 of the 34 TTM sites located in
Sweden, Denmark, the Netherlands, the United Kingdom
and Italy participates. The patients attended the follow up
at an institution or in their own home/nursing home. The
examiner was an occupational therapist, psychologist, a
study nurse or a physician. The examiners were trained at
specific trial meetings and written manuals were distrib-
uted. A centralized support-service and monitoring func-
tion was available throughout the study to prevent
missing data.
Ethical approval, informed consent and trial registration
Ethical applications for the TTM-trial and the present
cognitive sub-study have been approved in all participat-
ing countries. Written informed consent to participate in
the sub-study was obtained before the testing, 6 months
after the arrest. The TTM-trial and this sub-study are
registered at ClinicalTrials.gov (Identifier: NCT01020916
and NCT01946932).
Study population
The TTM-trial included adult, unconscious patients, with
sustained return of spontaneous circulation after cardiac
arrest, of a presumed cardiac origin. We estimated that
approximately 50% of patients included in the trial would
survive until 180 days follow-up [19]. Patients were
centrally randomized through a web-based system to tar-
get temperature management at 33°C or 36°C target















Figure 1 Predicted study inclusion in main trial, sub-study and controTTM survivors at the participating sites that met the in-
clusion criteria and who lacked exclusion criteria, with a
retained 1:1 randomization to the two temperature arms
since randomization was stratified for site (Figure 1). For
each patient included in the sub-study an informant was
asked to participate. The informant is defined as a relative
or a close friend with the potential to act as a caregiver if
needed.
A control group was recruited at 1:2 ratio for the CA-
patients (one control for two CA patients) from a cohort
of patients with ST-elevation myocardial infarction and
emergency percutaneous coronary intervention. The
controls were matched to the cardiac arrest patients for
country, age (best match), gender and time-point of
hospitalization (± 2 weeks). All recruitment and follow-up
of controls was centralized to one centre in each partici-
pating country. Also for the controls, an informant was
included.Exclusion criteria
An exclusion criterion for the TTM main trial is a pre-
arrest CPC-score ≥ 3 [19]. An additional exclusion
criterion for the sub-study is the inability to speak the
local language well enough to complete the tests without
an interpreter. The exclusion criteria for the control
patients are the same as for the TTM patients, and also
that they should not have sustained a cardiac arrest.Socio-demographical and medical variables
Socio-demographic and medical variables was obtained
at the follow-up or from the TTM database (Table 1).
Information about age, gender and the frequency of con-
























180 d after CA/MI
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▪Chronic heart failure (NYHA 3 or worse)






▪Asthma or chronic obstructive pulmonary disease
•Pre-hospital variables (only CA patients)
▪Location of cardiac arrest
▪Bystander witnessed arrest
▪Bystander cardiopulmonary resuscitation (CPR)
▪First monitored rhythm at arrival of emergency medical service
▪Use of active compression-decompression device
▪Time from cardiac arrest to start of basic life support
▪Time from arrest to start of advanced life support








•Pre-arrest Cerebral Performance Category (CPC)
•Level of education (≥12 years/<12 years)
•Medications at the time of the arrest (MI)
•Medications at the time of the follow-up






•Time from CA/MI to follow-up
•Employment status (pre-arrest/follow-up)
•Place of stay at the time of follow-up
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All patients alive at 6 months in the TTM trial were
followed up as previously described [19]. Tests and ques-
tionnaires of the main trial were presented prior to testsand questionnaires of the sub-study. The entire procedure
requires approximately 60–120 minutes (Table 2).
Cerebral Performance Categories scale (CPC) [20] is
considered the gold standard for neurological outcome
Table 2 Tests and questionnaires for the TTM main trial and cognitive sub-study





PS PO IS ER
Short Form Questionniare-36 version 2 SF-36v2© ■ ■ Health related quality of life ■ ■
Two Simple Questions TSQ ■ Everyday activities/cognition ■
Informant Questionnaire on Cognitive Decline IQCODE ■ Cognition ■
MiniMental Status Examination MMSE ■ Cognition ■
Cerebral Performance Category CPC ■ General neurological outcome ■
modified Rankin Scale mRS ■ General outcome ■
Rivermead Behavioural Memory Test RBMT ■ Memory ■
Symbol Digit Modalities Test SDMT ■ Attention/Concentration/Mental speed ■
Frontal Assessment Battery FAB ■ Executive functions ■
Hospital Anxiety and Depression Scale HADS© ■ Anxiety/Depression ■
Mayo-Portland Adaptability Inventory-4 MPAI-4 ■ Impairments/Adjustment/Participation ■
Zarit Burden Interview ZBI© ■ Caregiver burden ■
PS= Patient Subjective PO= Patient Objective IS= Informant Subjective ER= Examiner rating.
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measure outcome status and performance due to neuro-
logical function.
modified Rankin Scale (mRS) [22], is a similar scale
as the CPC but more directed towards global disabil-
ity. It focuses on dependence in ADL as well as
residual symptoms and is considered to be able to
detect even mild symptoms. Examiners in the TTM
study were encouraged to use a web based video
training [23,24] and the simple algorithm described
by Rittenberg [25].
The MiniMental Status Examination (MMSE) [26] is the
most widespread cognitive screening test available. It
covers 8 cognitive domains (orientation, registration, at-
tention, recall, language, reading, writing and drawing).
In the TTM study, the item serial 7 was used to test at-
tention since it is more sensitive to detect frontal lobe
dysfunction [27].
Two Simple Questions (TSQ) was developed for self-
estimation of outcome in stroke survivors, but was
modified to suit a CA population [28]. In a prior study,
the TSQ correlated with the results of cognitive screen-
ing and self-assessed HRQoL, but it was insensitive to
pre-arrest ADL dependency [28]. We therefore decided
to extend the TSQ with question 1b (Figure 2).
Informant Questionnaire on Cognitive Decline (IQCODE)
[29] is an instrument to detect cognitive decline reported
by an informant. It has not previously been used for
CA-patients and for this study we obtained permission
from the author of the questionnaire to modify the
original “compared to 10 years ago” to “compared to
before the cardiac arrest”.
Short Form Questionnaire© - 36 items, version 2 (SF-36v2)
[30] is a Health Related Quality of Life (HRQoL) ques-
tionnaire. All surviving patients in the main trial completedthe SF-36v2©. Additionally, in the cognitive sub-study the
informants completed SF-36v2© to measure their HRQoL.
Additional outcome measures in the cognitive sub-study
Rivermead Behavioural Memory Test (RBMT) [31] fo-
cuses on memory skills needed in everyday life. The
RBMT is available in several versions but the sub-study
used the original version since it was available in the
language of all participating countries.
Symbol Digit Modalities Test (SDMT) [32] is a test for
mental speed, attention and concentration. The SDMT
is available in a written and an oral form that could be
administered in parallel, this sub-study used mainly the
oral form.
Frontal Assessment Battery (FAB) [33] is a bedside
screening instrument for executive/frontal lobe dysfunc-
tion shown to correlate with more traditional tests
measuring single executive functions [34].
Hospital Anxiety and Depression Rating Scale© (HADS)
[35] is a questionnaire shown to be well suited to identify
anxiety and depression [36] and is commonly used for this
purpose in CA studies [37].
Mayo-Portland Adaptability Inventory-4 (MPAI-4) [38]
is a questionnaire based on the WHO’s international
classification of functioning, disability and health. It
measures different aspects of physical, cognitive, emo-
tional, behavioural and social problems following brain
injury, as well as obstacles to community integration and
social participation. It could be completed by the patient,
an informant or staff, all with similar levels of reliability
[39]. In this study, the patients rated their outcome (item
1–29), with the exception of the severely impaired,
where the informants completed the test.
Zarit Burden Interview© [40] is a 22 point scale that is
completed by the informant. It was developed for
2 Do you feel that you 
have made a complete 
mental recovery from 
your heart arrest?
(Yes/No)
1b If yes, is this situation 
new following your heart 
arrest?
(Yes/No)
1a In the last two weeks, 
did you require help from 
another person for your 
everyday activities? 
(Yes/No)
Figure 2 Two simple questions (TSQ).
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cognitively impaired older adults [41].
Statistical analysis and sample size calculation
In the primary analyses of cognitive function between
the two treatment groups and between the two treat-
ment groups and controls, three comparisons will be
made (RBMT, FAB, and SDMT). To correct for multiple
comparisons, the Bonferroni-Holm method with a crit-
ical p-value of 0.017 will be used. If the data are nor-
mally distributed or possible to transform to normal
distribution, the t-test and ANOVA will be used. If a
normal distribution cannot be obtained, we will apply
non-parametric test methods (Wilcoxon Mann Whitney/
Kruskal Wallis). Descriptive statistics will be used for
the baseline characteristics of the sub-study partici-
pants (treatment groups and controls), the whole TTM
population and patients not-included the sub-study.
Initial randomization will be maintained by inclusion
of non-responders (CPC score including dead) in the
first comparison between the two temperature arms. We
will use multiple imputations for missing values to pre-
vent bias due to incomplete or absent test results from
the most severely impaired patients. In the comparison
between the two treatment groups and controls, only
survivors will be included. Confounders will be adjusted
for by multiple regression.
In a previous case–control study [6] the RBMT
score was 20% lower in the CA population. To cor-
rectly identify a 10% difference (2.4/24points on
RBMT, SD 5 [6]) between the two temperature arms,
with the type I error probability set to 0.017, we esti-
mated a need for 100 patients in each treatment
group and a power of 83,5%. There are no similar
studies with FAB and SDMT.
Cognitive impairment measured by the three tests:
RBMT, FAB and SDMT will be correlated to participa-
tion in society (MPAI-4/return to work), HRQoL for
patients and caregivers (SF-36v2©), and caregivers
feeling of burden (ZBI©).Trial status and time-line
Enrolment in the TTM-trial started November 2010 and
inclusion stopped at target 950 patients January 2013. The
first follow-up of this sub-study was performed in June
2011 and the last patient is estimated to be included
September/October 2013. Analyses of the sub-study
outcome measures will commence after publication of the
main trial results which is expected to be in November 2013.
Discussion
Global brain injury and cognitive dysfunction are well
described consequences of cardiac arrest but the preva-
lence of impairment and the consequences for patients
and their relatives have never before been described in a
large international cohort. Utilising a relevant control-
group with similar risk factors for cognitive impairment
our study will also add information on the prevalence of
cognitive problems among patients with myocardial in-
farction only. The actual impact of the CA will be
expressed as the difference between CA patients and
controls and is likely to be considerably smaller than in
previous trials without a control-group.
The primary aim of the TTM-trial is to assess whether
survival is affected by systemic cooling to 33°C compared
to a controlled temperature of 36°C. In addition, neuro-
logical outcome is compared between the two treatment
groups by the established but crude outcome scales CPC
and mRS. The CPC-scale is best suited to identify
moderate to severe impairment and has less ability to dif-
ferentiate in the higher end of none to mild impairment
[3,15]. This sub-study will add systematic cognitive testing
in survivors from the two temperature arms with the
original randomization maintained. Consequently more
subtle neuroprotective effects of systemic cooling may be
revealed.
This sub-study is an extension of the follow-up platform
that we use in the TTM-main trial. In order to enable
follow-up of all patients in this large international inten-
sive care trial, we choose tests that were possible to per-
form in a short period of time, with limited training and
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backgrounds.
The simple test battery of the TTM main trial is based
on a model that has been in use in one of our institutions
in recent years. Our experience is that this test battery is
easily integrated as a screening tool during normal ICU
follow-up and sensitive enough to identify the majority of
patients who have significant cognitive problems.
Although the MMSE test has known ceiling effects and
may be insensitive to mild to moderate cognitive difficul-
ties [3], our hypothesis is that the combination of objective
(MMSE), subjective (TSQ) and proxy ratings (IQCODE)
will increase the ability to identify patients with cognitive
impairment in the main TTM trial. An advantage with the
IQCODE is that it can be used for patients who are unable
to participate in cognitive testing [42].
Instruments for the assessment of cognitive function
in the sub-study were chosen to assess the cognitive do-
mains mostly affected by CA (memory, attention, execu-
tive functions) [3]. They have previously been used in
similar studies [6,43-46] and are all easy to administer
with some training. In addition, we added tools for more
subjective areas of participation in society and caregiver’s
health and judgements of burden.
In a small study by Middlekamp and co-workers [9], it
has been proposed that participation in society may be af-
fected by cognitive disability due to CA. However, cognitive
impairment may have different effects on participation in
society according to which activities, roles and environ-
ment the patient needs to return to [47]. The large sample
size of this sub-study will substantially increase the
available information regarding this association.
Cognitive dysfunction may be perceived as a greater
problem by caregivers than amongst affected patients e.g.
due to lack of insight. This may lead to feelings of in-
creased burden and poor health amongst caregivers [5].
Relatives to CA patients were found to have increased
levels of anxiety [4] and decreased HRQoL [5]. Moreover,
family members of critically ill patients in general may
have psychological distress due to posttraumatic stress
[48]. Whether caregiver distress is related to the degree of
cognitive impairment in patients has not previously been
investigated.
We choose to perform the follow-up at 6 months. At this
time-point most of the spontaneous recovery has occurred,
and any dysfunction that remains will be long term [49,50].
Since it is impossible to estimate the precise pre-arrest cog-
nitive function of our patients, we use a matched control
group to evaluate the influences of cardiac arrest according
to previous recommendations [51,52]. Patients with myo-
cardial infarction were found to lack significant long-term
memory impairments [6,53,54], but to have a similar pattern
of HRQoL as patients having suffered cardiac arrest [55].
In addition, they share the same cardiovascular riskfactors and risk of mood disturbances due to acute
hospitalization, which makes them a relevant population
to study as controls.
Mild to moderate cognitive impairment in a CA-
survivor may easily be overlooked by treating physicians
[50] as these patients are more often regarded as having
cardiological rather than neurological disease [4]. The
simple cognitive screening model used in the TTM trial is
easy to apply in any clinical setting and with minimal re-
source utilization. The results from this sub-study could
be used to evaluate whether the suggested screening
model is able to identify patients at risk. There is a clear
need for a structured approach to identify CA-patients
with cognitive problems [50,56,57] and to increase the
knowledge about how these will affect patients and their
families, so clinicians can target appropriate support. If
the screening model proves to be accurate/specific enough
it could have a large clinical impact as a consequence of
its simplicity. This study will generate important informa-
tion concerning neurological outcome and quality of life
for CA survivors and their families, as well as the impact
of temperature management.
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